IQVIA Hldgs Stock: A Deep Dive Into Analyst Perspectives (13 Ratings)
Pfizer And GSK's ViiV Healthcare's Two-Drug HIV Treatment Matches Gilead's Three-Drug Combo In Major Trial
10 Health Care Stocks Whale Activity In Today's Session
Viiv's Dovato as Effective as Gilead' Biktarvy for HIV but With Less Weight Gain
Amgen, Garmin Among Relative Market Leaders Poised to Outperform in Coming Months: BTIG
MAIA Biotechnology's Lung Cancer Drug Shows Promising Long-Term Benefits In Advanced Patients
Here's How Much $100 Invested In Vertex Pharmaceuticals 5 Years Ago Would Be Worth Today
These Analysts Boost Their Forecasts On IQVIA After Better-Than-Expected Earnings
Moderna Adds The Carlyle Group's David Rubenstein as Board Member
IQVIA Hldgs Analyst Ratings
$100 Invested In This Stock 15 Years Ago Would Be Worth $5,100 Today
AnaptysBio Investigational Arthritis Drug Might Have Better Efficacy Profile Than Eli Lilly's: Analyst
US Stocks Rebound As Tech Surges, CrowdStrike Continues Selloff, Oil Hits 1-Month Lows: What's Driving Markets Monday?
Ionis' Rare Development Disorder Drug Candidate 'Could Be Differentiated' From Peer Ultragenyx: Analyst
Breaking Down Gilead Sciences: 10 Analysts Share Their Views
Check Out What Whales Are Doing With MRNA
IQVIA Posts Upbeat Earnings, Joins Terex, Reddit And Other Big Stocks Moving Higher On Monday
Gilead Sciences Analyst Ratings
IQVIA 'Is A Solid Investment' With Strong Competitive Positioning, Analyst Says After Better Than Expected Q2 Earnings
Oppenheimer Outlined a Top Buy and Sell Idea for Each S&P Sector